Boots to Launch Medical Cannabis Prescribing Service in UK

Boots is launching a medical cannabis prescribing service, marking a first for a UK high street pharmacy according to the Guardian.

The online service, named SureLeaf, is being offered to UK patients aged 25 and older who have an eligible condition such as chronic pain, anxiety, or insomnia.

To access the service, patients are invited to start an online assessment. Boots said that a clinical team will review their suitability before inviting them to a video consultation with a consultant.

Boots said any prescription would be “independently reviewed by a multidisciplinary clinical team that includes a second, independent consultant, before treatment begins.” The pharmacy also said that any patient wishing to be prescribed medical cannabis must first have tried conventional treatments without success, and that patients will be regularly reviewed.

Boots Pharmacy Selling Weed Cannabis And Launching Today — Mp3 Music Awards TV

The chain is launching the service alongside a collaborative research programme with the University of Nottingham to examine patient outcomes, prescribing practices, and experience in treating chronic pain.

Jamie Kerruish, Boots’ chief healthcare officer, said: “Millions of people live with ongoing pain and, for some, conventional treatments do not provide adequate symptom relief. This can affect everyday life, from working and sleeping well to spending time with family and doing the things they enjoy.”

Kerruish added: “Ultimately, it’s about helping people explore appropriate options that could help them better manage their symptoms and improve their quality of life.”

Dr David Gwynne, the medical director of Boots’ online service, said: “Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis.”

Gwynne also said: “SureLeaf has, therefore, been designed with strong clinical safeguards and specialist oversight at every stage, so treatment is only considered for patients where it is clinically appropriate. Our priority is to ensure patients receive responsible, clinically led care, from their initial specialist assessment through to ongoing monitoring and review once treatment begins.”

The prescription of cannabis-derived medicines was legalised in 2018, and private clinics have treated patients with them for years. On the NHS, only people with rare forms of epilepsy, certain chemotherapy side-effects, and certain multiple sclerosis symptoms can obtain the treatment.

Photo of author

Alexandra Hartman Editor-in-Chief

Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.

France Beat South Africa After Disallowed Arendse Try